Synchronous and Metachronous Second Primary Tumors in Head and Neck

Definition and Classification

Warren and Gates Criteria (Classic Definition)

1. Histologic confirmation of malignancy in both the index and secondary tumors
2. The two tumors must be anatomically separated by normal mucosa (some authors require at least 1.5-2 cm of normal tissue between tumors)
3. The possibility of the SPM being a metastasis from the index tumor must be excluded

Note: When both tumors arise at the same anatomic subsite, some investigators additionally require the SPM to appear at least 3-5 years after the index tumor, or require molecular analysis to confirm distinct clonal origin.

Incidence

• The annual risk of SPM following index head and neck SCC is 1-7% per year, and this risk persists for at least 10 years
• The cumulative risk of developing an SPM is at least 20%, and is higher in those who continue tobacco and alcohol use
• The overall incidence for synchronous and metachronous lesions in patients with head and neck malignancy is approximately 14%
• Of all SPMs, 80% are metachronous, and 50% of these present within the first 2 years of initial treatment
• SPMs are the second leading cause of death in head and neck cancer patients; one-quarter to one-third of deaths are attributable to SPM
• Patients with stage I or II head and neck SCC are statistically more likely to die of an SPM than from the index tumor itself

Common Sites

• Head and neck - most frequent site overall
• Esophagus - especially after oral cavity and oropharyngeal primaries (cervical esophagus most common); the overall incidence of synchronous/metachronous esophageal cancer in head and neck cancer patients is ~3%
• Lung - particularly significant in laryngeal cancer patients; an isolated pulmonary nodule in a larynx cancer patient should be considered an SPM until proven otherwise

For oral cavity and oropharyngeal primaries - second primary is most often in the cervical esophagus. New dysphagia or odynophagia in these patients must prompt barium swallow or esophagoscopy.

Pathogenesis - Field Cancerization

• Histologic changes identical to those in the malignant cells are found in clinically normal-appearing adjacent mucosa
• The entire mucosa of the upper aerodigestive tract is exposed to the same carcinogens (tobacco, alcohol), predisposing it to widespread genetic damage
• A single transforming event produces a cell with a growth advantage that spreads throughout the mucosal surface - multiple tumors do not require multiple independent transforming events
• The initial clone spreads submucosally and each region may accumulate further distinct mutations, resulting in geographically separate but genetically related tumors
• Molecular studies (Bedi et al.) using X-chromosome inactivation and microsatellite analysis confirmed that both original and second malignancies arose from a single clone

Risk Factors

• Tobacco (cigarette, bidi, smokeless) - most important
• Alcohol - acts synergistically with tobacco
• Prior head and neck SCC (the single greatest risk factor)
• Continued tobacco/alcohol use after treatment dramatically increases cumulative risk
• Prior radiotherapy is associated with SPTs in a small number of cases (radiation-induced second primaries)

Surveillance and Detection

• Clinical follow-up every 1-3 months in the first year, then gradually less frequent
• PET-CT is especially useful - can detect synchronous and metachronous second primaries in the head/neck, esophagus, and lung
• Panendoscopy (direct laryngoscopy + esophagoscopy + bronchoscopy) - performed at time of initial staging to exclude synchronous lesions
• Barium swallow or esophagoscopy if new dysphagia/odynophagia
• Chest X-ray/CT for lung surveillance

Treatment Principles

• Each SPM is treated as a separate entity, as if it were the index tumor at that anatomic site
• Metachronous SPMs - patients often have already received full-dose radiation; surgical salvage is the preferred modality when feasible
• Re-irradiation - an option in carefully selected patients with minimal prior toxicity and good performance status
• Survival depends on stage and site: SPMs arising in the head and neck carry significantly better survival than those in the lung or esophagus

Key Points to Remember for Exam

1. Synchronous = within 6 months | Metachronous = after 6 months
2. Warren and Gates criteria - 3 components
3. 80% of all SPMs are metachronous
4. Field cancerization (Slaughter 1953) - single clone, clonal spread
5. Overall incidence ~14%; cumulative risk ~20%
6. Most common sites: head/neck > esophagus > lung
7. Larynx cancer - lung is the most common site of synchronous/metachronous SPT; isolated lung nodule = SPT until proven otherwise
8. SPM = 2nd leading cause of death in HNSCC
9. PET-CT and panendoscopy for detection